FibroBiologics Wins U.S. Patent for Fibroblast Tech to Boost Islet Transplant Survival
FBLG sits 53% above its 52-week low of $0.62.
Summary
The USPTO granted FibroBiologics a patent covering methods to use fibroblasts to improve engraftment and long-term function of transplanted pancreatic islets — a key challenge in islet transplantation for Type 1 diabetes. This adds to the company's 270+ patent portfolio and directly supports its clinical pipeline, including the ongoing Phase 1/2 CYWC628 trial for diabetic foot ulcers. The patent could broaden the company's addressable market into cell transplantation beyond diabetes. With a market cap around $6.5M and shares at $0.95, intellectual property milestones are material for a micro-cap biotech. The company recently closed a $3M private placement, and this patent strengthens its scientific positioning ahead of further clinical data.
At the time of this announcement, FBLG was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.62 to $12.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.